The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...
GSK tried again with the combination regimens, and two separate Phase 3 trials yielded promising results in 2024. In the ...
(Reuters) -The U.S. Food and Drug Administration has approved British drugmaker GSK's blood cancer drug, Blenrep, in one ...
A pharmaceutical factory which ceased production earlier this year has been bought by Britain's biggest defence firm. BAE ...
The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...
Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback